Analyzing Market Sentiment Towards Insmed (INSM) Stock

This afternoon we watched Insmed drop -3.9% to a price of $62.0 per share. The Large-Cap Pharmaceutical company is now trading -18.71% below its average target price of $76.27. Analysts have set target prices ranging from $60.0 to $90.0 per share for Insmed, and have given the stock an average rating of buy.

Insmed has an average level of shares sold short, at 7.2% of its total share float. The stock's short ratio (also called days to cover) is 2.14. The company's insiders own 1.01% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 95.2% of Insmed's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Insmed

Date Reported Holder Percentage Shares Value
2024-03-31 Vanguard Group Inc 10% 14,509,235 $899,572,570
2024-03-31 Blackrock Inc. 8% 11,799,701 $731,581,462
2024-03-31 Price (T.Rowe) Associates Inc 7% 10,769,366 $667,700,692
2024-03-31 FMR, LLC 6% 9,318,894 $577,771,428
2024-03-31 State Street Corporation 4% 5,905,127 $366,117,874
2024-03-31 Deep Track Capital, Lp 3% 4,783,679 $296,588,098
2024-03-31 Palo Alto Investors Lp 3% 4,423,369 $274,248,878
2024-03-31 William Blair Investment Management, LLC 3% 4,214,719 $261,312,578
2024-03-31 Macquarie Group Limited 3% 3,899,504 $241,769,248
2024-03-31 Franklin Resources, Inc. 2% 3,567,013 $221,154,806
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.